A randomized study comparing cisplatin or carboplatin with etoposide in patients with advanced non-small-cell lung cancer: European Organization for Research and Treatment of Cancer Protocol 07861.
作者： Jean Klastersky , Jean-Paul Sculier , Hendrik Lacroix , Gérard Dabouis , Gérard Bureau
DOI: 10.1200/JCO.1990.8.9.1556
关键词: Cisplatin 、 Clinical trial 、 Oncology 、 Etoposide 、 Medicine 、 Carboplatin 、 Carcinoma 、 Lung cancer 、 Survival analysis 、 Cancer 、 Internal medicine
摘要: The European Organization for Research and Treatment of Cancer (EORTC) Lung Working Party conducted a randomized trial comparing cisplatin (CDDP; 120 mg/m2, day 1) carboplatin (CBDCA; 325 in combination with etoposide (VP16; 100 days 1, 2, 3) advanced non-small-cell lung cancer (NSCLC). Two hundred twenty-eight patients were eligible survival 202 assessable response. We obtained 27 objective responses (ORs; 27%) the CDDP arm 16 102 (16%) CBDCA (P = .07). There was no significant difference survival. Toxicity, consisting mainly myelosuppression renal function impairment, significantly increased receiving treatment. conclude that plus VP16 more active but also toxic than NSCLC.
ulb.ac.be
sci-hub.se 参考文章(15)
David R. Cox, Regression Models and Life-Tables Springer Series in Statistics. ,vol. 34, pp. 527- 541 ,(1992) , 10.1007/978-1-4612-4380-9_37
Jean Klastersky, E. Longeval, Robert De Jager, High-dose cisplatin with fluid and mannitol-induced diuresis in advanced lung cancer: A phase II clinical trial of the EORTC lung cancer working party (Belgium) Cancer treatment reports. ,vol. 64, pp. 1341- 1346 ,(1980)
J Klastersky, J P Sculier, G Bureau, P Libert, P Ravez, G Vandermoten, J Thiriaux, J Lecomte, R Cordier, G Dabouis, Cisplatin versus cisplatin plus etoposide in the treatment of advanced non-small-cell lung cancer. Lung Cancer Working Party, Belgium. Journal of Clinical Oncology. ,vol. 7, pp. 1087- 1092 ,(1989) , 10.1200/JCO.1989.7.8.1087
E. L. Kaplan, Paul Meier, Nonparametric Estimation from Incomplete Observations Springer Series in Statistics. ,vol. 53, pp. 319- 337 ,(1992) , 10.1007/978-1-4612-4380-9_25
James F. Bishop, Carboplatin in lung cancer Lung Cancer. ,vol. 5, pp. 8- 14 ,(1989) , 10.1016/0169-5002(89)90188-8
Elias Tueni, Jean-Paul Sculier, Jean Klastersky, Phase I study of a carboplatin-etoposide combination in advanced thoracic cancer. European Journal of Cancer and Clinical Oncology. ,vol. 24, pp. 963- 967 ,(1988) , 10.1016/0277-5379(88)90143-5
Jean-Paul Sculier, Jean Klastersky, Progress in chemotherapy of non-small cell lung cancer European Journal of Cancer and Clinical Oncology. ,vol. 20, pp. 1329- 1333 ,(1984) , 10.1016/0277-5379(84)90049-X
Emile Longeval, Jean Klastersky, Combination chemotherapy with cisplatin and etoposide in bronchogenic squamous cell carcinoma and adenocarcinoma. A study by the EORTC lung cancer working party (Belgium) Cancer. ,vol. 50, pp. 2751- 2756 ,(1982) , 10.1002/1097-0142(19821215)50:12<2751::AID-CNCR2820501210>3.0.CO;2-3
R Peto, M C Pike, P Armitage, N E Breslow, D R Cox, S V Howard, N Mantel, K McPherson, J Peto, P G Smith, Design and analysis of randomized clinical trials requiring prolonged observation of each patient. II. analysis and examples. British Journal of Cancer. ,vol. 35, pp. 1- 39 ,(1977) , 10.1038/BJC.1977.1
J Klastersky, J P Sculier, P Ravez, P Libert, J Michel, G Vandermoten, P Rocmans, Y Bonduelle, M Mairesse, T Michiels, A randomized study comparing a high and a standard dose of cisplatin in combination with etoposide in the treatment of advanced non-small-cell lung carcinoma. Journal of Clinical Oncology. ,vol. 4, pp. 1780- 1786 ,(1986) , 10.1200/JCO.1986.4.12.1780